Autres domaines


Clinical characteristics of Merkel cell carcinoma at diagnosis in 195 patients: the AEIOU features - 24/04/13

Doi : 10.1016/j.jaad.2007.11.020 
Michelle Heath, MD a, Natalia Jaimes, MD a, Bianca Lemos, MD a, Arash Mostaghimi, MD d, Linda C. Wang, MD, JD d, Pablo F. Peñas, MD, PhD e, Paul Nghiem, MD, PhD a, b, c,
a University of Washington, Division of Dermatology, Seattle, Washington 
b Seattle Cancer Care Alliance, Seattle, Washington 
c Fred Hutchinson Cancer Research Center, Seattle, Washington 
d Dana Farber/Brigham and Women’s Cancer Center, Boston, Massachusetts 
e Westmead Hospital, University of Sydney, Sydney, Australia 

Reprint requests: Paul Nghiem, MD, PhD, University of Washington, 815 Mercer St, Seattle, WA 98109.



Merkel cell carcinoma (MCC) is an aggressive skin cancer with a mortality of 33%. Advanced disease at diagnosis is a poor prognostic factor, suggesting that earlier detection may improve outcome. No systematic analysis has been published to define the clinical features that are characteristic of MCC.


We sought to define the clinical characteristics present at diagnosis to identify features that may aid clinicians in recognizing MCC.


We conducted a cohort study of 195 patients given the diagnosis of MCC between 1980 and 2007. Data were collected prospectively in the majority of cases, and medical records were reviewed.


An important finding was that 88% of MCCs were asymptomatic (nontender) despite rapid growth in the prior 3 months (63% of lesions) and being red or pink (56%). A majority of MCC lesions (56%) were presumed at biopsy to be benign, with a cyst/acneiform lesion being the single most common diagnosis (32%) given. The median delay from lesion appearance to biopsy was 3 months (range 1-54 months), and median tumor diameter was 1.8 cm. Similar to earlier studies, 81% of primary MCCs occurred on ultraviolet-exposed sites, and our cohort was elderly (90% >50 years), predominantly white (98%), and often profoundly immune suppressed (7.8%). An additional novel finding was that chronic lymphocytic leukemia was more than 30-fold overrepresented among patients with MCC.


The study was limited to patients seen at a tertiary care center. Complete clinical data could not be obtained on all patients. This study could not assess the specificity of the clinical characteristics of MCC.


To our knowledge, this study is the first to define clinical features that may serve as clues in the diagnosis of MCC. The most significant features can be summarized in an acronym: AEIOU (asymptomatic/lack of tenderness, expanding rapidly, immune suppression, older than 50 years, and ultraviolet-exposed site on a person with fair skin). In our series, 89% of primary MCCs had 3 or more of these findings. Although MCC is uncommon, when present in combination, these features may indicate a concerning process that would warrant biopsy. In particular, a lesion that is red and expanding rapidly yet asymptomatic should be of concern.

Le texte complet de cet article est disponible en PDF.

Abbreviations used : AEIOU, CLL, MCC, SEER, UV


 Dr Jaimes is currently affiliated with Dermatology, Universidad Pontificia Bolivariana, Medellín, Colombia. Dr Mostaghimi is currently affiliated with Beth Israel Deaconess Medical Center, Boston, Mass.
 Supported by Harvard/National Cancer Institute Skin Cancer Specialized Program of Research Excellence (SPORE), University of Washington Merkel Cell Carcinoma Research Fund, National Institutes of Health K02-AR050993, and American Cancer Society Jerry Wachter Fund.
 Conflicts of interest: None declared.
 Selected and limited preliminary descriptive results presented in abstract form at the 2007 Annual Meeting of the Society for Investigative Dermatology, in Los Angeles, California, on May 12, 2007.

© 2008  American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer

    Export citations

  • Fichier

  • Contenu

Vol 58 - N° 3

P. 375-381 - mars 2008 Retour au numéro
Article précédent Article précédent
  • New viral vaccines for dermatologic disease
  • Christine Orlova Urman, Alice B. Gottlieb
| Article suivant Article suivant
  • Increased cancer antigen 27.29 (CA27.29) level in patients with mycosis fungoides
  • Putao Cen, Madeleine Duvic, Philip R. Cohen, Razelle Kurzrock

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?


Mon compte

Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.